中国全科医学2024，Vol.27Issue(36)：4505-4514,4521,11.DOI:10.12114/j.issn.1007-9572.2024.0171
脂蛋白a在心血管疾病中的研究新进展
Latest Progress of Lipoprotein(a)in Cardiovascular Diseases
摘要
Abstract
Lipoprotein(a)[Lp(a)]is significantly related to atherosclerotic cardiovascular disease(ASCVD),but it is unclear whether clinical agents that lower Lp(a)can reduce the risk of ASCVD.Here,we systematically reviewed the structure,function,genetic characteristics and detection status of Lp(a),discussed the relationship of Lp(a)with ASCVD,aortic valve stenosis and other cardiovascular diseases,and summarized new advance of Lp(a)-lowering therapies.The structural composition of Lp(a)indicates that Lp(a)may promote atherosclerosis,inhibit fibrinolytic reaction and promote inflammation.Multiple evidence from genetic studies and epidemiological studies supports that Lp(a)is significantly associated with an increased risk of ASCVD and major adverse cardiovascular events.In addition,Lp(a)is also associated with other cardiovascular diseases such as aortic valve stenosis.At present,several emerging drugs that lower Lp(a)are in clinical trials and may further reduce residual cardiovascular risk.This paper hopes to offer new thought for the study of Lp(a),and provide a basis for the monitoring and management of blood lipids.关键词
心血管疾病/动脉粥样硬化/脂蛋白a/遗传学/主要不良心血管事件/降脂蛋白a药物Key words
Cardiovascular diseases/Atherosclerosis/Lipoprotein(a)/Genetics/Major adverse cardiovascular events/Lipoprotein(a)-lowering drugs分类
医药卫生引用本文复制引用
李婕,丁虎..脂蛋白a在心血管疾病中的研究新进展[J].中国全科医学,2024,27(36):4505-4514,4521,11.基金项目
"十四五"国家重点研发计划项目(2021YFC2500604) （2021YFC2500604）
